Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Next Previous
Trial Profile

High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Antineoplastics; Cyclophosphamide; Daunorubicin; Doxorubicin; Mercaptopurine; Prednisolone; Prednisone; Tioguanine; Vincristine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 01 Feb 2024 Results assessing osteonecrosis incidence, characteristics, and risk factors in patients 1-30 years with newly diagnosed high-risk B-ALL on COG AALL0232, published in the Leukemia.
  • 07 Jun 2022 Results of an analysis assessing impact of dose modification based on various factors using data from two clinical studies: NCT00075725 and NCT00408005 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 02 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top